Bosh sahifaNTLA • NASDAQ
add
Intellia Therapeutics Inc
Yopilish kursi
12,02 $
Kunlik diapazon
9,93 $ - 11,43 $
Yillik diapazon
9,93 $ - 34,87 $
Bozor kapitalizatsiyasi
1,04 mlrd USD
Oʻrtacha hajm
2,36 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(USD) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Daromad | 9,11 mln | -24,02% |
Joriy xarajat | 30,50 mln | 3,73% |
Sof foyda | -135,71 mln | -11,04% |
Sof foyda marjasi | -1,49 ming | -46,15% |
Har bir ulushga tushum | -1,34 | 2,90% |
EBITDA | -142,16 mln | -10,36% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
(USD) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 658,11 mln | -23,01% |
Jami aktivlari | 1,17 mlrd | -5,63% |
Jami passivlari | 210,74 mln | 2,33% |
Umumiy kapital | 962,62 mln | — |
Tarqatilgan aksiyalar | 101,85 mln | — |
Narxi/balansdagi bahosi | 1,27 | — |
Aktivlardan daromad | -30,61% | — |
Kapitaldan daromad | -33,80% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(USD) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Sof foyda | -135,71 mln | -11,04% |
Operatsiyalardan naqd pul | -84,84 mln | 16,32% |
Sarmoyadan naqd pul | -7,71 mln | -109,70% |
Moliyadan naqd pul | 82,19 mln | 330,28% |
Naqd pulning sof oʻzgarishi | -10,35 mln | -272,58% |
Boʻsh pul | -35,80 mln | 44,08% |
Haqida
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
CEO
Tashkil etilgan
2014
Sayt
Xodimlar soni
526